In this Help Net Security interview, Michael Gorelik, CTO and Head of Malware Research at Morphisec, provides insights into the business impact of vulnerabilities. Read more...
Read MoreSAN JOSE, Calif.–(BUSINESS WIRE)–Stellar Cyber, the innovator of Open XDR, today announced a new partnership with BlackBerry to deliver a comprehensive threat detection and response solution enabling Managed Security Service Providers (MSSPs) and enterprises to simplify their security stacks, increase productivity, and reduce the time it takes to detect and respond to cyber threats. As part of this partnership, Stellar Cyber and BlackBerry continue to drive joint development to help customers optimize their security posture. Read more...
Read MoreTEL AVIV, Israel, Dec. 18, 2023 /PRNewswire/ — Perception Point, a leading provider of advanced threat prevention across digital communication channels, announced today it has achieved overall leader ranking for its Advanced Email Security solution in KuppingerCole Analysts AG’s Leadership Compass for Email Security. The report additionally named Perception Point a leader in three categories including Innovation Leadership, Product Leadership, and Technology Leadership. Perception Point clearly leads the market in the Product/Innovation Matrix, demonstrating the company’s strong ability to innovate and deliver enterprise-grade security for the modern workspace; protecting organizations from the top threat vector: email-borne attacks. Read...
Read MoreAfter a sticky period Highcon has received the sort of endorsement that only money can buy. Its shareholders and partners have backed the Israeli start up business to the tune of $10 million, money that allows the company to complete development of a new generation of corrugated and carton digital cutting and creasing machines and to continue a drive to change the printed packaging industry. Its proposition is tantamount to a revolution for a sector where digital printing is only now starting to have an impact. That this revolution has taken a lot longer to arrive than many predicted helps account for the stretched finances. Read...
Read MoreLARKSPUR, Calif.–(BUSINESS WIRE)–Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of best-in-class IL-2 therapeutics, today announced plans to initiate the Phase 2 portion of its Phase 1/2 clinical trial of AU-007 in patients with unresectable locally advanced or metastatic solid tumor cancers of the skin and kidney. AU-007 is a human IgG1 monoclonal antibody designed using artificial intelligence to harness the power of interleukin-2 (IL-2) to eradicate solid tumors. Read...
Read More
